HemaQuest Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.hemaquest.com
Effects of HQK-1001 in Patients With Sickle Cell Disease
- Conditions
- Sickle Cell DiseaseSickle Cell AnemiaSickle Cell DisordersHemoglobin S DiseaseSickling Disorder Due to Hemoglobin S
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT01601340
- Locations
- 🇨🇦
University Health Network Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Georgia Health Sciences University, Augusta, Georgia, United States
A Study of HQK-1001 in Patients With Sickle Cell Disease
- Conditions
- Sickle Cell DiseaseSickle Cell AnemiaSickle Cell DisordersHemoglobin S DiseaseSickling Disorder Due to Hemoglobin S
- Interventions
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01322269
- Locations
- 🇺🇸
LSU Health Sciences Center - Feist Weiller Cancer Center, Shreveport, Louisiana, United States
🇺🇸Univerisity of Texas Southwestern Medical Center at Dallas - Pediatric Hematology Oncology, Dallas, Texas, United States
🇨🇦The Hospital for Sick Children, Toronto, Ontario, Canada
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
- Conditions
- Lymphoid MalignanciesLymphoproliferative Disorders
- Interventions
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00992732
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸LPCH/Stanford, Palo Alto, California, United States
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
- Conditions
- EBV LymphomasLympho-proliferative Diseases
- Interventions
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00917826
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00842088
- Locations
- 🇺🇸
Texas Children's Cancer Center and Hematology Service, Houston, Texas, United States
🇺🇸Medical College of Georgia, Augusta, Georgia, United States
🇺🇸Johns Hopkins School of Medicine, Baltimore, Maryland, United States
Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2011-05-20
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00790127
- Locations
- 🇹🇭
Siriraj Hospital, Bangkok, Bangkoknoin District, Thailand
🇱🇧Chronic Care Center, Beirut, Lebanon
Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2009-01-16
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT00717262
- Locations
- 🇺🇸
Charles River Clinical Services Northwest, Tacoma, Washington, United States
A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- HemaQuest Pharmaceuticals Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00614016
- Locations
- 🇺🇸
Charles River Clinical Services Northwest, Inc., Tacoma, Washington, United States